Xceleron pioneered the use of AMS analysis in pre-clinical and clinical development. AMS analysis provides critical human metabolism data at an early stage in the development process. The bulk of the operations are now run out of Maryland, US. Albion exited Xceleron in January 2017

Xceleron announces new investment and move to purpose-built laboratories in U.S.
Xceleron achieves significant growth in 2009 raises funds and expands core capabilities to fuel further growth
Xceleron Names Michael Butler as President & CEO
Close Ventures management and Foursome Invest £2.0 million in leading UK pharmaceutical services company
Ed Lascelles